Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug TAK-279 targets rare, severe psoriasis in phase 3 trial

NCT ID NCT06323356

Completed Disease control Sponsor: Takeda Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 31, 2026 · Updated 3 times

Summary

This phase 3 trial tests the drug TAK-279 in 18 adults with generalized pustular psoriasis or erythrodermic psoriasis, two rare and severe forms of the disease. All participants receive the drug for up to 52 weeks to see if it clears skin symptoms and is safe. The study is open-label, meaning everyone knows they are getting the active treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
TAK-279 (a drug taken by mouth)
What this could lead to
If it works, this could provide a new treatment option for people with rare, severe forms of psoriasis that are hard to control.
What could go wrong
This is a small, open-label study with only 18 participants, so results may not apply to everyone. The drug may cause side effects or not work as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ERYTHRODERMIC PSORIASIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

generalized pustular psoriasis psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ERYTHRODERMIC PSORIASIS GENERALIZED PUSTULAR PSORIASIS

Contacts and locations

Locations

  • Fujita Health University Hospital

    Toyoake, Aichi-ken, Japan

  • Fukuoka University Hospital

    Fukuoka, Japan

  • Hospital of the University of Occupational and Environmental Health, Japan

    Kitakyushu, Fukuoka, Japan

  • Isesaki Municipal Hospital

    Isesaki, Gunma, Japan

  • Juntendo University Urayasu Hospital

    Urayasu, Chiba, Japan

  • Kansai Medical University Hospital

    Hirakata, Osaka, Japan

  • Kimitsu Chuo Hospital

    Kisarazu, Chiba, Japan

  • Kobe University Hospital

    Kobe, Hyōgo, Japan

  • Mie University Hospital

    Tsu, Mie-ken, Japan

  • Nagoya City University Hospital

    Nagoya, Aichi-ken, Japan

  • Nippon Life Hospital

    Osaka, Japan

  • Okayama University Hospital

    Okayama, Japan

  • Osaka Metropolitan University Hospital

    Osaka, Japan

  • Saitama Medical University Hospital

    Iruma, Saitama, Japan

  • St.Luke's International Hospital

    Chūō, Tokyo, Japan

  • Teikyo University Hospital

    Itabashi-ku, Tokyo, Japan

  • The Jikei University Hospital

    Minato-ku, Tokyo, Japan

  • Tokai University Hospital

    Isehara, Kanagawa, Japan

  • Tokyo Medical University Hospital

    Shinjuku-ku, Tokyo, Japan

  • University Hospital, Kyoto Prefectural University of Medicine

    Kyoto, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.